stockrow
Friday 6 November 2026
Export YCBD’s income statement to Excel — free account
cbdMD, Inc.
YCBD Healthcare Drug Manufacturers Specialty & Generic
cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024.
- Revenue
- +20.6%
- EPS
- +47.6%
- Free cash flow
- +34.8%
Quarter to June 2026, against a year earlier
0.42
0.03
+7.69%
Follow YCBD
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.34 | 0.39 | 0.64 | 0.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.09) | (10.70) | (14.96) | (45.02) | |
P/B ratio |
0.87 | 0.83 | 1.35 | 1.50 | |
Price to Tangible BV |
1.18 | 1.12 | 1.72 | 2.13 | |
EV/Sales |
0.35 | 0.38 | 0.59 | 0.57 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.34) | (3.02) | (5.74) | (7.56) | |
EV/FCF |
(2.98) | (2.75) | (5.07) | (6.44) | |
Quick Ratio |
1.26 | 1.42 | 1.62 | 1.03 | |
Current Ratio |
2.50 | 2.82 | 2.94 | 2.05 | |
Net Debt/EBITDA |
3.07 | 6.98 | (26.00) | 8.93 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.82 | 1.72 | 1.64 | 1.83 | |
Operating CF/Net income |
0.37 | 0.82 | 2.50 | 0.35 | |
Capex/Depreciation |
(0.04) | (0.01) | (0.40) | (0.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.17 | 0.19 | 0.16 | 0.20 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.09% | |
Graham Net Nets |
0.39 | 0.70 | 0.44 | 0.31 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(45.66%) | (54.85%) | (164.88%) | (326.11%) | |
Free Cash Flow Yield |
(34.86%) | (35.26%) | (18.11%) | (15.74%) | |
Revenue per Share |
0.52 | 0.54 | 0.56 | 0.53 | |
Operating CF per Share |
(0.04) | (0.07) | (0.09) | (0.03) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.11) | (0.03) | |
Cash per Share |
0.20 | 0.25 | 0.38 | 0.25 | |
Shareholders Equity per Share |
0.77 | 0.89 | 1.00 | 0.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.77 | 0.89 | 1.00 | 0.81 | |
Free Cash Flow |
(0.46) | (0.73) | (0.98) | (0.24) | |
Working Capital |
4.62 | 5.42 | 5.39 | 3.36 | |
Capital Expenditures |
(0.02) | (0.01) | (0.16) | 0.00 | |
Net Current Asset Value |
2.76 | 5.42 | 5.39 | 3.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.36 | 1.31 | 1.20 | 1.01 | |
Average Payables |
1.35 | 1.34 | 1.02 | 1.36 | |
Average Inventory |
3.04 | 2.99 | 2.55 | 2.55 | |
Average Assets |
11.52 | 11.60 | 11.66 | 10.50 | |
Average Common Equity |
7.16 | 4.97 | 5.39 | 4.59 |
Columns are period end dates · fundamentals updated 26 Oct 2026